Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9
- 30 April 1996
- journal article
- review article
- Published by Elsevier BV in General Pharmacology: The Vascular System
- Vol. 27 (3), 421-429
- https://doi.org/10.1016/0306-3623(95)00118-2
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Expression of NAD(P)H: quinone oxidoreductase and glutathione S-transferases α and π in human renal cell carcinoma and in kidney cancer-derived cell linesCarcinogenesis: Integrative Cancer Research, 1994
- Potentiation of EO9 anti-tumour activity by hydralazineEuropean Journal Of Cancer, 1993
- A systematic study on the chemical stability of the novel indoloquinone antitumour agent EO9International Journal of Pharmaceutics, 1993
- NAD(P)H:Quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissuesCancer and Metastasis Reviews, 1993
- Bioreductive drugs as post-irradiation sensitizers: Comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9International Journal of Radiation Oncology*Biology*Physics, 1992
- Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinonesInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Bioactivation of Mitomycin C by Xanthine Dehydrogenase From EMT6 Mouse Mammary Carcinoma TumorsJNCI Journal of the National Cancer Institute, 1992
- Transcriptional regulation of the rat NAD(P)H:quinone reductase geneJournal of Biological Chemistry, 1991
- Gradient high-performance liquid chromatographic assay for the determination of the novel indoloquinone antitumour agent E09 in biological specimensJournal of Chromatography B: Biomedical Sciences and Applications, 1990
- [56] DT diaphorasePublished by Elsevier BV ,1967